文献速递关节外科

阿司匹林与强效抗凝药用于静脉血栓栓塞预防的90天不良事件比较:72,288例全膝关节和35,142例全髋关节置换患者的队列研究

Comparison of 90-Day Adverse Events Associated With Aspirin and Potent Anticoagulation Use for Venous Thromboembolism Prophylaxis: A Cohort Study of 72,288 Total Knee and 35,142 Total Hip Arthroplasty Patients.
PubMed 文献 · J Arthroplasty · 2023-02-18

基于Kaiser Permanente全关节置换登记系统2009至2019年72,288例全膝关节置换和35,142例全髋关节置换患者的队列研究,采用倾向评分加权逻辑回归评估90天静脉血栓栓塞。在全膝关节置换中,阿司匹林不劣于低分子肝素(OR=0.77,单侧95%CI上限=1.09)和华法林(OR=0.64,上限=0.90),但与Xa因子抑制剂相比无证据支持非劣效;全髋关节置换结果一致。结论认为阿司匹林在初次全关节置换包括较高静脉血栓栓塞风险患者中有效且安全。

要点

  • 在全膝关节置换中,阿司匹林不劣于低分子肝素(OR=0.77,单侧95%CI上限=1.09)和华法林(OR=0.64,上限=0.90)。
  • 在全髋关节置换中,阿司匹林不劣于低分子肝素(OR=0.59,单侧95%CI上限=0.75)和华法林(OR=0.69,上限=0.89)。
  • 在较高风险全膝关节置换中,阿司匹林不劣于华法林(OR=0.54,上限=0.81),但与低分子肝素和Xa因子抑制剂相比缺乏非劣效证据。

核心结论

  • 阿司匹林在初次全关节置换中用于静脉血栓栓塞预防有效且安全,包括在被认为静脉血栓栓塞风险较高的患者中。

研究设计与样本

  • 来自Kaiser Permanente全关节置换登记系统的队列研究,纳入2009至2019年72,288例全膝关节置换和35,142例全髋关节置换患者。
  • 识别的药物包括阿司匹林、Xa因子抑制剂、低分子肝素和华法林,每位患者分配经验证的静脉血栓栓塞风险评分。
  • 采用倾向评分加权逻辑回归评估90天静脉血栓栓塞,非劣效检验边界为1.25,使用单侧95%CI上限。

主要发现

  • 全膝关节置换中,阿司匹林不劣于低分子肝素(OR=0.77,单侧95%CI上限=1.09)和华法林(OR=0.64,上限=0.90);与Xa因子抑制剂相比无证据支持阿司匹林非劣效。
  • 全髋关节置换中结果一致:阿司匹林不劣于低分子肝素(OR=0.59,单侧95%CI上限=0.75)和华法林(OR=0.69,上限=0.89)。
  • 较高风险全膝关节置换中,阿司匹林不劣于华法林(OR=0.54,单侧95%CI上限=0.81),但与低分子肝素和Xa因子抑制剂相比缺乏非劣效证据。
  • 较高风险全髋关节置换中,阿司匹林与任何强效抗凝药相比均缺乏非劣效证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While aspirin is acceptable for venous thromboembolism (VTE) prophylaxis following total joint arthroplasty in most patients, more potent agents are used in patients considered higher risk for VTE. We evaluated the efficacy and safety of aspirin versus potent anticoagulation agents following total knee arthroplasty (TKA) and total hip arthroplasty (THA). METHODS: A cohort study of 72,288 TKA and 35,142 THA from the Kaiser Permanente Total Joint Replacement Registry was performed (2009 to 2019). Identified medications were aspirin, factor Xa inhibitors, low-molecular-weight heparin (LMWH), and warfarin. A validated VTE risk score was assigned to each patient. Propensity score-weighted logistic regressions were used to evaluate 90-day VTEs. Noninferiority testing was performed with a margin of 1.25 using the upper bound (UB) of the 1-sided 95% CI. RESULTS: For TKA, aspirin was not inferior to LMWH (odds ratio [OR] = 0.77, UB = 1.09) and warfarin (OR = 0.64, UB = 0.90); there was no evidence to support noninferiority of aspirin compared to factor Xa inhibitors. Findings were consistent for THA (LMWH: OR = 0.59, UB = 0.75; warfarin: OR = 0.69, UB = 0.89). TKA was considered higher risk for VTE, whereas aspirin use demonstrated noninferiority compared to warfarin (OR = 0.54, UB = 0.81), we lacked evidence of noninferiority when compared to LMWH and factor Xa inhibitors. We lacked evidence of noninferiority of aspirin versus any potent anticoagulation in higher-risk THA. CONCLUSION: Aspirin was found to be effective and safe for VTE prevention in primary total joint arthroplasty, including in patients considered higher risk for VTE. LEVEL OF EVIDENCE: III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Singh G, Prentice HA, Winston BA, et al. Comparison of 90-Day Adverse Events Associated With Aspirin and Potent Anticoagulation Use for Venous Thromboembolism Prophylaxis: A Cohort Study of 72,288 Total Knee and 35,142 Total Hip Arthroplasty Patients. J Arthroplasty. 2023. PMID: 36805118. doi:10.1016/j.arth.2023.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。